|
시장보고서
상품코드
2117969
스마트 인슐린 펜 : 시장 인사이트, 경쟁 구도 및 시장 예측(2034년)Smart Insulin Pens - Market Insights, Competitive Landscape, and Market Forecast - 2034 |
||||||
DelveInsight
개요:
- 스마트 인슐린 펜 시장은 2025년에 9억 2,000만 달러로 추산되며, 2034년까지 24억 2,000만 달러에 달할 것으로 전망됩니다. 이러한 성장의 배경에는 전 세계 당뇨병 부담의 증가, 환자와 의사의 연결형 및 데이터 기반 인슐린 투여에 대한 선호도 상승, 그리고 스마트 펜, 지속형 혈당 모니터(CGM), 디지털 당뇨병 관리 플랫폼 간의 연계 확대가 있습니다.
- 세계 스마트 인슐린 펜 시장은 2026년부터 2034년까지의 예측 기간 동안 연평균 성장률(CAGR) 11.4%로 성장하고 있습니다.
- 연결 방식별로는 2025년에 블루투스 지원 부문이 63%의 점유율을 차지하며 스마트 인슐린 펜 시장을 주도했습니다.
- 최종사용자별로는 2025년에 ‘병원·진료소’ 부문이 41%의 점유율을 차지하며 스마트 인슐린 펜 시장을 주도했습니다.
- 유통 채널별로는 2025년에 ‘병원·소매 약국’ 부문이 53%의 점유율을 차지하며 스마트 인슐린 펜 시장을 주도했습니다.
- 북미는 2025년에 44%의 점유율을 차지하며 전 세계 스마트 인슐린 펜 시장의 매출을 견인했고, 지역별로는 전 세계에서 가장 높은 시장 점유율을 기록했습니다.
스마트 인슐린 펜이란 재사용 가능하거나 일회용 인슐린 투여 기기, 혹은 기존 펜에 부착하는 연결형 어태치먼트 캡을 말하며, 각 주사의 투여량, 날짜, 시간을 자동으로 기록하고 블루투스, NFC, USB 또는 클라우드 연결을 통해 연동된 모바일 애플리케이션으로 이 정보를 전송합니다. 인슐린 투여를 디지털화함으로써, 이러한 기기는 투여량 추적, 투여 누락 알림, 볼러스 투여량 계산, 체내 잔여 인슐린량 추정 및 지속 혈당 모니터와의 연동을 지원하여, 당뇨병 환자와 의료진이 더 정보에 입각하고 데이터에 기반한 치료 결정을 내릴 수 있도록 돕습니다. 시장은 연결 방식별로 블루투스 지원, NFC 지원, USB 연결 및 무선/클라우드 연결 펜으로 분류됩니다. 또한, 최종사용자별로는 병원, 진료소, 재택 간호 환경, 당뇨병 전문 센터, 외래 진료 센터 등이 포함되며, 유통 채널별로는 병원, 소매 약국, 당뇨병 클리닉 및 센터, E-Commerce 등이 포함됩니다. 전 세계 당뇨병 환자 수의 급증, 맞춤형 디지털 당뇨병 관리에 대한 수요 증가, 그리고 기기와 앱 간, 기기와 CGM 간의 연결성 가속화를 배경으로, 스마트 인슐린 펜은 커넥티드 당뇨병 관리 생태계에서 점점 더 중심적인 존재가 되고 있습니다.
스마트 인슐린 펜 시장의 주요 성장 촉진요인
- 세계 당뇨병 부담의 증가에 따라 대상 환자층이 확대되고 있습니다. 국제당뇨병연맹(IDF)의 추산에 따르면, 2024년에는 5억 8,900만 명의 성인이 당뇨병을 앓고 있으며, 이 수치는 2050년까지 8억 5,300만 명에 달할 것으로 예측됩니다.
- 기존 인슐린 펜에 비해 의사와 환자가 연결형 인슐린 투여를 선호하는 경향이 강해지고 있어 보급이 가속화되고 있습니다. 투여량을 자동으로 기록함으로써 투여 누락이나 중복 투여가 줄어들고, 치료 순응도가 향상되기 때문입니다.
- 스마트 인슐린 펜과 연속 혈당 모니터링 시스템 간의 연동이 확대되고 있으며, 예를 들어 메드트로닉(Medtronic)사의 ‘InPen’과 덱스콤(Dexcom)이나 프리스타일 리브레(FreeStyle Libre) 센서 간의 호환성 등을 통해, 하루에 여러 번 주사를 맞는 환자에게 풍부한 데이터를 바탕으로 한, 거의 폐쇄 루프에 가까운 관리 경험이 실현되고 있습니다.
- 노보 노르디스크(Novo Nordisk), 사노피(Sanofi), 일라이 릴리(Eli Lilly)와 같은 주요 인슐린 제조사들은 환자의 지속적인 사용을 촉진하고 가치 기반 의료 계약을 지원하기 위해 자사의 인슐린 투여 생태계에 연결 기능을 직접 통합하고 있습니다.
- 스마트폰 보급률의 상승과 당뇨병 관리 앱의 증가로 인해, 특히 재택 간호 및 외래 진료 현장에서 커넥티드 펜의 도입 장벽이 낮아지고 있습니다.
- 미국 및 유럽 일부 지역에서는 커넥티드형 인슐린 투여 기기에 대한 유리한 환급 제도 마련과 보험 적용 범위 확대가 진행되고 있어, 합리적인 가격으로의 접근성과 처방량이 증가하고 있습니다.
- 애보트(Abbott)의 빅풋 바이오메디컬(Bigfoot Biomedical) 인수와 노보노르디스크(Novo Nordisk)의 바이오코프(Biocorp) 인수 등 합병, 인수, 라이선싱 활동이 활발해지고 있으며, 이에 따라 스마트 펜 기술은 더 대규모의 당뇨병 관리 및 제약 플랫폼 내에 통합되어 상용화가 가속화되고 있습니다.
스마트 인슐린 펜 시장의 성장에 기여하는 요인
시장 촉진요인
세계 당뇨병 부담 증가 및 인슐린 의존 인구 증가
스마트 인슐린 펜 시장의 가장 큰 촉진요인은 전 세계 당뇨병 환자 수의 방대한 규모와 지속적인 증가입니다. 국제당뇨병연맹(IDF)의 추정에 따르면, 2024년에는 5억 8,900만 명의 성인이 당뇨병을 앓고 있으며, 이는 전 세계 성인의 약 9명 중 1명에 해당합니다. 이 수치는 2050년까지 8억 5,300만 명에 달할 것으로 예측됩니다. 이 환자층의 상당 부분은 1형 당뇨병과 인슐린이 필요한 2형 당뇨병을 모두 아우르며, 펜을 이용한 하루 여러 번의 인슐린 주사에 의존하고 있어, 이로 인해 커넥티드 펜 기술의 사용자 기반은 거대하며 지속적으로 확대되고 있습니다. 선진국과 신흥 시장 모두에서 인슐린 치료를 받는 환자 수가 증가하고, 임상의들이 치료 강화를 위해 객관적인 투여 데이터를 점점 더 요구함에 따라, 투여 정보를 자동으로 기록 및 전송하는 스마트 인슐린 펜에 대한 수요도 이에 따라 확대되어 2034년까지 시장 성장을 뒷받침할 것입니다.
개인화된 데이터 기반 당뇨병 관리에 대한 수요 증가
스마트 인슐린 펜은 당뇨병 관리 분야에서 오랫동안 제기되어 온 과제, 즉 연속 혈당 모니터가 혈당 수치에 대해 이미 제공하고 있는 것과 동등한 수준의 객관적이고 실시간 인슐린 투여 데이터의 부재를 해소합니다. 이러한 기기는 모든 주사의 양과 시기를 자동으로 기록함으로써 수기 투여 기록을 불필요하게 만들고, 투여 누락이나 중복을 줄이며, 환자와 의료 제공자 모두가 혈당 추이와 함께 주사 이력을 확인할 수 있게 해줍니다. 이 기능을 통해 보다 개별화된 투여량 조정이 가능해지며, 기저 인슐린 투여 누락 등의 패턴을 더 정확하게 파악할 수 있어 진료 효율도 향상됩니다. 보험사 및 의료 제공자가 가치 중심적이고 데이터 기반의 당뇨병 관리를 점점 더 중시하는 가운데, 스마트 펜이 제공하는 객관적인 투여 기록에 대한 수요는 제1형 및 2형 당뇨병 환자 모두에서 지속적으로 증가하고 있습니다.
시장 제약요인
견고한 기초 모멘텀에도 불구하고, 스마트 인슐린 펜 시장은 중대한 제약에 직면해 있습니다. 기존 인슐린 펜에 비해 스마트 펜 및 연결형 추가 캡의 초기 비용과 단가가 높은 점은 여전히 도입의 장벽으로 작용하고 있습니다. 특히 가격에 민감하고 환자 본인 부담 의료비가 높은 신흥 시장에서 이러한 경향이 두드러집니다. 연결형 인슐린 투여 기기에 대한 보험 환급은 지역에 따라 일관성이 없으며, 보험 적용 범위의 차이로 인해 임상적 유효성이 충분히 입증된 경우에도 환자가 비용을 부담해야만 하는 상황이 발생하여 보급을 저해하는 요인이 되고 있습니다. 개인의 건강 정보 및 투여 정보의 전송·저장에 따른 데이터 개인정보 보호 및 사이버 보안에 대한 우려는 일부 환자와 의료 제공자에게 주저함을 야기하고 있습니다. 또한, 서로 다른 제조사의 펜, 앱, CGM(지속 혈당 모니터링) 시스템 간의 상호 운용성 문제는 사용자 경험을 단편화하고 임상 워크플로우를 복잡하게 만들 가능성이 있습니다. 저·중소득 지역의 환자, 나아가 일부 의료 제공자들 사이에서 스마트 펜 기술에 대한 인지도가 낮은 점은 확립된 시장 이외의 지역에서의 보급을 저해하고 있으며, 스마트폰과의 페어링에 의존하고 있다는 점은 스마트폰을 안정적으로 이용할 수 없는 환자를 배제하는 결과로 이어지고 있습니다. 일라이 릴리(Eli Lilly)가 2026년에 ‘Tempo Personalized Diabetes Management Platform’의 제공을 종료하기로 결정한 것은, 충분한 자금력을 갖춘 커넥티드 펜 프로그램조차도 영향을 받을 수 있는 상업적 및 보험 급여 측면의 불확실성을 여실히 드러내고 있습니다. 당뇨병 유병률의 증가와 디지털 헬스의 보급이라는 근본적인 촉진요인이 여전히 확고하게 존재함에도 불구하고, 비용, 보험 급여, 데이터 보안, 상호 운용성, 그리고 낮은 인지도와 같은 장벽들이 복합적으로 작용하여 도입 속도는 둔화되고 있습니다.
자주 묻는 질문
목차
제1장 스마트 인슐린 펜 시장 : 소개
제2장 스마트 인슐린 펜 시장 : 주요 요약
제3장 스마트 인슐린 펜 시장 : 주요 요인 분석
제4장 AI, 지정학, 무역 및 경제 동향
제5장 규제 분석
제6장 Porter's Five Forces 분석
제7장 스마트 인슐린 펜 시장 : 평가
제8장 스마트 인슐린 펜 시장 : 경쟁 구도
제9장 스마트 인슐린 펜 시장 : 스타트업 자금 조달 및 투자 동향
제10장 스마트 인슐린 펜 시장 : 기업 개요 및 제품 프로파일
제11장 KOL의 견해
제12장 프로젝트 접근법
제13장 DelveInsight 소개
제14장 면책사항 및 문의
KSM 26.08.31Smart Insulin Pens Market Summary
Overview:
- The Smart Insulin Pens market is estimated at USD 0.92 billion in 2025 and is projected to reach USD 2.42 billion by 2034. Growth is anchored in the rising global burden of diabetes, growing patient and physician preference for connected, data-driven insulin delivery, and expanding integration between smart pens, continuous glucose monitors (CGMs), and digital diabetes-management platforms.
- The global Smart Insulin Pens market is growing at a CAGR of 11.4% during the forecast period from 2026 to 2034.
- By connectivity type, the Bluetooth-Enabled segment dominated the Smart Insulin Pens market with a 63% share in 2025.
- By end-user, the Hospitals & Clinics segment dominated the Smart Insulin Pens market with a 41% share in 2025.
- By distribution channel, the Hospital & Retail Pharmacy segment dominated the Smart Insulin Pens market with a 53% share in 2025.
- North America dominated the global Smart Insulin Pens market revenue with a 44% share in 2025, representing the highest regional market share globally.
A smart insulin pen is a reusable or disposable insulin delivery device, or a connected add-on cap for a conventional pen, that automatically captures the dose, date, and time of each injection and transmits this information via Bluetooth, NFC, USB, or cloud connectivity to a companion mobile application. By digitizing insulin dosing, these devices support dose-tracking, missed-dose alerts, bolus calculation, insulin-on-board estimation, and integration with continuous glucose monitors, helping people with diabetes and their clinicians make more informed, data-backed treatment decisions. The market is organized by connectivity type across Bluetooth-enabled, NFC-enabled, USB-connected, and wireless/cloud-connected pens; by end-user, spanning hospitals and clinics, homecare settings, diabetes specialty centers, and ambulatory care centers; and by distribution channel, including hospital and retail pharmacies, diabetic clinics and centers, and e-commerce. Driven by the surging global diabetes population, rising demand for personalized digital diabetes management, and accelerating device-to-app and device-to-CGM connectivity, smart insulin pens are becoming an increasingly central component of the connected diabetes-care ecosystem.
Smart Insulin Pens Market Key Growth Drivers
- The rising global burden of diabetes is expanding the addressable patient population, with the International Diabetes Federation estimating 589 million adults living with diabetes in 2024, a figure projected to reach 853 million by 2050.
- Growing physician and patient preference for connected insulin delivery over conventional pens is accelerating adoption, as automatic dose-logging reduces missed or duplicated doses and improves treatment adherence.
- Expanding integration between smart insulin pens and continuous glucose monitoring systems, such as Medtronic InPen's compatibility with Dexcom and FreeStyle Libre sensors, is creating a data-rich, near-closed-loop management experience for people on multiple daily injections.
- Major insulin manufacturers, including Novo Nordisk, Sanofi, and Eli Lilly, are embedding connectivity directly into their branded insulin delivery ecosystems to strengthen patient retention and support value-based care contracting.
- Rising smartphone penetration and the proliferation of diabetes-management apps are lowering the adoption barrier for connected pens, particularly in homecare and ambulatory settings.
- Favorable reimbursement developments and expanding insurance coverage for connected insulin delivery devices in the United States and parts of Europe are improving affordability and prescription volumes.
- Growing merger, acquisition, and licensing activity, including Abbott's acquisition of Bigfoot Biomedical and Novo Nordisk's acquisition of Biocorp, is consolidating smart-pen technology within larger diabetes-care and pharmaceutical platforms and accelerating commercialization.
Key Companies in Smart Insulin Pens Market
The competitive landscape is led by the following active manufacturers:
- Emperra GmbH E-Health Technologies
- Jiangsu Delfu Medical Device Co., Ltd.
- Medtronic
- Novo Nordisk A/S
- Pendiq
- Sanofi
- Berlin-Chemie
- Bigfoot Biomedical
- Digital Medics Pty Ltd.
- Eli Lilly and Company
Factors Contributing to the Growth of the Smart Insulin Pens Market
Market Drivers
Rising Global Diabetes Burden and Insulin-Dependent Population
The single most powerful driver of the Smart Insulin Pens market is the sheer scale and continued growth of the global diabetes population. The International Diabetes Federation estimates that 589 million adults were living with diabetes in 2024, equivalent to roughly one in nine adults worldwide, with the figure projected to rise to 853 million by 2050. A substantial share of this population, spanning both type 1 diabetes and insulin-requiring type 2 diabetes, relies on multiple daily insulin injections delivered by pen, creating a large and expanding installed base for connected pen technology. As insulin-treated populations grow across both developed and emerging markets, and as clinicians increasingly seek objective dosing data to guide therapy intensification, demand for smart insulin pens that automatically capture and transmit dosing information expands in step, anchoring market growth through 2034.
Growing Demand for Personalized, Data-Driven Diabetes Management
Smart insulin pens address a long-standing gap in diabetes care: the absence of objective, real-time insulin dosing data comparable to what continuous glucose monitors already provide for glucose levels. By automatically logging the size and timing of every injection, these devices eliminate manual dose diaries, reduce missed or duplicated doses, and allow both patients and healthcare providers to review injection history alongside glucose trends. This capability supports more personalized dose titration, better identification of patterns such as skipped basal doses, and more productive clinic visits. As payers and providers increasingly emphasize value-based, data-informed diabetes care, demand for the objective dosing record that smart pens provide continues to strengthen across both type 1 and type 2 diabetes populations.
Market Restraints
Despite strong underlying momentum, the Smart Insulin Pens market faces material constraints. The higher upfront and per-unit cost of smart pens and connected add-on caps relative to conventional insulin pens remains a barrier to adoption, particularly in price-sensitive and emerging markets where out-of-pocket healthcare spending is high. Reimbursement for connected insulin delivery devices remains inconsistent across geographies, and coverage gaps can leave patients responsible for costs that limit uptake even where clinical benefit is well established. Data privacy and cybersecurity concerns associated with the transmission and storage of personal health and dosing information create hesitancy among some patients and providers, and interoperability challenges between different manufacturers' pens, apps, and CGM systems can fragment the user experience and complicate clinical workflows. Limited awareness of smart-pen technology among patients and even some healthcare providers in low- and middle-income regions constrains penetration outside established markets, and reliance on smartphone pairing excludes patients without consistent smartphone access. Eli Lilly's 2026 decision to discontinue its Tempo Personalized Diabetes Management Platform underscores the commercial and reimbursement uncertainty that can affect even well-resourced connected-pen programs. Together, these cost, reimbursement, data-security, interoperability, and awareness barriers temper the pace of adoption, even as the underlying drivers of rising diabetes prevalence and digital health adoption remain firmly intact.
Smart Insulin Pens Market Segment Analysis
The smart insulin pens market by connectivity type (bluetooth-enabled, nfc-enabled, usb-connected, wireless/cloud-connected), end-users (hospitals & clinics, homecare settings, diabetes specialty centers, ambulatory care centers, others), distribution channels (hospital & retail pharmacy, diabetic clinics & centers, e-commerce, others), and geography (North America, Europe, Asia-Pacific, and Rest of World).
By Connectivity Type
Dominant Subsegment: Bluetooth-Enabled.
The Bluetooth-enabled segment accounted for 63% of the Smart Insulin Pens market in 2025. Bluetooth-enabled pens are the leading connectivity type because Bluetooth Low Energy offers reliable, low-power, continuous pairing with smartphones, enabling automatic, real-time transfer of dosing data without requiring the patient to actively tap or scan the device. Leading products such as Medtronic's InPen, Novo Nordisk's NovoPen 6 and NovoPen Echo Plus, and Eli Lilly's Tempo Smart Button all rely on Bluetooth connectivity, giving the segment the deepest catalog of commercially available, clinically validated devices. Bluetooth's broad compatibility with both iOS and Android diabetes-management apps, together with its established role in CGM data transmission, makes it the natural default for manufacturers building integrated glucose-and-insulin data platforms. While NFC-enabled pens are the fastest-growing connectivity type, valued for their simplicity and lower power requirements in markets such as Germany where Emperra's ESYSTA pioneered Bluetooth-enabled dosing, the breadth of Bluetooth's device ecosystem and its central role in CGM integration secure the segment's leadership across the forecast period.
By End-Users
Dominant Subsegment: Hospitals & Clinics.
The hospitals & clinics segment accounted for 41% of the Smart Insulin Pens market in 2025. Hospitals and clinics are the leading end-user category because they serve as the primary point of diabetes diagnosis, insulin therapy initiation, and device prescription, giving endocrinologists and diabetes educators direct influence over which connected pens patients adopt. Clinical settings also generate the greatest immediate value from objective dosing data, since physicians use pen-generated injection histories to titrate therapy, identify adherence gaps, and support insurance documentation during in-person visits. Hospitals and specialty diabetes clinics were also the first sites to pilot smart-pen programs such as the Bigfoot Unity Program, reinforcing clinical familiarity and referral pathways. While homecare settings are the fastest-growing end-user category as more patients self-manage therapy at home with continuous app-based support, the central role of hospitals and clinics in device prescription and therapy titration secures the segment's leadership across the forecast period.
Smart Insulin Pens Market Region Analysis
Dominant Region: North America
North America accounted for 44% of the global Smart Insulin Pens market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a high prevalence of diagnosed diabetes, strong insurance and reimbursement coverage for connected insulin delivery devices, and the presence of leading manufacturers including Medtronic, Eli Lilly, and Abbott (following its acquisition of Bigfoot Biomedical). The United States in particular benefits from broad adoption of the InPen and Bigfoot Unity systems, extensive CGM penetration that creates natural pull-through demand for CGM-compatible smart pens, and FDA clearance pathways that have supported a steady stream of new connected-device launches. Strong direct-to-consumer digital health marketing, employer and payer-sponsored diabetes management programs, and deep integration with popular diabetes apps further reinforce the region's leadership across the forecast period.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is the fastest-growing region in the Smart Insulin Pens market. The region's elevated CAGR is driven by its enormous and rapidly growing diabetic population, led by China and India, alongside rising healthcare expenditure, expanding private insurance coverage, and growing local manufacturing capability. China's Jiangsu Delfu Medical Device Co., Ltd. is scaling domestic production of connected insulin delivery devices, Japan is seeing steady adoption of digital diabetes-management tools within its advanced healthcare system, and India's large and increasingly urban diabetic population is driving demand for affordable connected pens and smart-cap add-ons. Government initiatives to modernize chronic-disease management and growing awareness of digital health tools among both patients and physicians are accelerating adoption, positioning Asia-Pacific as the principal source of incremental market growth over the forecast period.
Regional Commentary
North America
North America accounted for 44% of the global Smart Insulin Pens market revenue in 2025. The United States dominates on the strength of its high diagnosed-diabetes prevalence, favorable device reimbursement, deep CGM penetration, and the concentration of leading manufacturers including Medtronic, Eli Lilly, and Abbott, while Canada contributes steady growth supported by its public healthcare system's gradual expansion of connected-device coverage.
Europe
Europe is a large and technologically advanced regional market, anchored by Germany, home to Emperra GmbH E-Health Technologies, whose ESYSTA pen was among the first Bluetooth-enabled smart insulin pens to receive European Commission approval, and Pendiq, another German developer of connected insulin delivery devices. Berlin-Chemie and Sanofi's SoloSmart, developed with Biocorp, extend the region's connected-pen footprint across Germany, France, the United Kingdom, Italy, and Spain, supported by established EU medical device regulatory frameworks and growing statutory health-insurance coverage for digital diabetes tools.
Asia-Pacific
Asia-Pacific is the fastest-growing region, propelled by its large and expanding diabetic population across China, Japan, India, South Korea, and Australia. China's Jiangsu Delfu Medical Device Co., Ltd. is expanding domestic manufacturing and distribution of connected insulin pens, Japan's advanced healthcare infrastructure supports steady premium-device adoption, and India's growing private healthcare and insurance sector is broadening access to smart insulin delivery technology, together accelerating regional market growth.
Rest of World
The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier for smart insulin pens. Rising diabetes prevalence, gradually improving healthcare infrastructure, and growing awareness of digital diabetes-management tools, led by companies such as Digital Medics Pty Ltd., extending connectivity solutions into new markets, are broadening access, while international distribution partnerships and expanding private insurance coverage support the gradual build-out of regional demand.
Smart Insulin Pens Market Competitive Landscape
The Smart Insulin Pens market is classified as Moderately Fragmented. A group of large, diversified medical device and pharmaceutical companies with global distribution, including Medtronic, Novo Nordisk A/S, Sanofi, and Eli Lilly and Company, anchor the top tier by embedding connectivity into branded insulin ecosystems, while specialized connected-device developers such as Emperra GmbH E-Health Technologies, Pendiq, Berlin-Chemie, Bigfoot Biomedical, Jiangsu Delfu Medical Device Co., Ltd., and Digital Medics Pty Ltd. compete through focused smart-cap and smart-pen innovation, regional manufacturing strength, and niche connectivity partnerships.
The competitive landscape can be evaluated across the following dimensions:
- Market concentration: Moderately fragmented, with large insulin and device manufacturers leading distribution scale alongside specialized connected-pen innovators.
- Leading players: Medtronic, Novo Nordisk A/S, Sanofi, and Eli Lilly and Company anchor the top tier through branded insulin ecosystem integration and global reach.
- Geographic reach: Leaders operate global distribution networks, while regional specialists such as Emperra, Pendiq, and Berlin-Chemie maintain strong footholds in the German and broader European market.
- Product portfolio strength: Top players offer integrated pen-plus-app-plus-CGM ecosystems spanning dose logging, bolus calculation, and insulin-on-board tracking.
- Connectivity technology: Ownership of validated Bluetooth, NFC, and cloud-connectivity platforms, together with CGM interoperability, is a decisive competitive advantage.
- Strategic partnerships: Tie-ups between insulin manufacturers and device or app developers, such as Sanofi and Biocorp's SoloSmart and Medtronic InPen's Dexcom and FreeStyle Libre integrations, extend ecosystem reach.
- M&A activity: Active consolidation, including Abbott's acquisition of Bigfoot Biomedical and Novo Nordisk's acquisition of Biocorp, is concentrating connected-pen technology within larger diabetes-care platforms.
- Manufacturing capabilities: Precision dose-sensing electronics, miniaturized Bluetooth and NFC modules, and regulatory-grade quality manufacturing are key competitive moats.
- Innovation focus: CGM integration, AI-assisted dose guidance, expanded smartphone and wearable compatibility, and next-generation smart-cap retrofits for disposable pens.
Smart Insulin Pens Market Recent Developmental Activities
In 2026, Eli Lilly and Company announced the discontinuation of its Tempo Personalized Diabetes Management Platform, including the Tempo Smart Button, Tempo Pens, and TempoSmart app, by the end of 2026, shifting affected patients toward standard KwikPen insulin delivery and the Lilly Insulin Value Savings Card. Strategic significance: Signals the commercial and reimbursement challenges connected-pen programs can face even when backed by a major insulin manufacturer.
Smart Insulin Pens Market Segmentation
Smart Insulin Pens Market by Connectivity Type
- Bluetooth-Enabled
- NFC-Enabled
- USB-Connected
- Wireless/Cloud-Connected
Smart Insulin Pens Market by End-Users
- Hospitals & Clinics
- Homecare Settings
- Diabetes Specialty Centers
- Ambulatory Care Centers
- Others
Smart Insulin Pens Market by Distribution Channels
- Hospital & Retail Pharmacy
- Diabetic Clinics & Centers
- E-commerce
- Others
Smart Insulin Pens Market by Geography
- North America Smart Insulin Pens Market
- United States Smart Insulin Pens Market Size in USD million (2023-2034)
- Canada Smart Insulin Pens Market Size in USD million (2023-2034)
- Mexico Smart Insulin Pens Market Size in USD million (2023-2034)
- Europe Smart Insulin Pens Market
- Germany Smart Insulin Pens Market Size in USD million (2023-2034)
- United Kingdom Smart Insulin Pens Market Size in USD million (2023-2034)
- France Smart Insulin Pens Market Size in USD million (2023-2034)
- Italy Smart Insulin Pens Market Size in USD million (2023-2034)
- Spain Smart Insulin Pens Market Size in USD million (2023-2034)
- Rest of Europe Smart Insulin Pens Market Size in USD million (2023-2034)
- Asia-Pacific Smart Insulin Pens Market
- China Smart Insulin Pens Market Size in USD million (2023-2034)
- Japan Smart Insulin Pens Market Size in USD million (2023-2034)
- India Smart Insulin Pens Market Size in USD million (2023-2034)
- Australia Smart Insulin Pens Market Size in USD million (2023-2034)
- South Korea Smart Insulin Pens Market Size in USD million (2023-2034)
- Rest of Asia-Pacific Smart Insulin Pens Market Size in USD million (2023-2034)
- Rest of the World (RoW) Smart Insulin Pens Market
- Middle East Smart Insulin Pens Market Size in USD million (2023-2034)
- Africa Smart Insulin Pens Market Size in USD million (2023-2034)
- South America Smart Insulin Pens Market Size in USD million (2023-2034)
Key Takeaways from the Smart Insulin Pens Market Report Study
- Market size analysis for the current Smart Insulin Pens market size (2025), and market forecast for 9 years (2026 to 2034).
- Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
- Key companies dominating the global Smart Insulin Pens market.
- Various opportunities available for competitors in the Smart Insulin Pens market space.
- What are the top-performing segments in 2025? How will these segments perform in 2034?
- Which are the top-performing regions and countries in the current Smart Insulin Pens market scenario?
- Which are the regions and countries where companies should concentrate their opportunities for Smart Insulin Pens market growth in the future?
Target audience who can benefit from this Smart Insulin Pens market report study
- Smart Insulin Pens product providers
- Research organizations and consulting companies
- Smart Insulin Pens therapeutics-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in Smart Insulin Pens
- Various end-users who want to know more about the Smart Insulin Pens market and the latest technological developments in the Smart Insulin Pens market.
Frequently Asked Questions:
Q1. What is the growth rate of the Smart Insulin Pens market?
The Smart Insulin Pens market is projected to expand at a CAGR of 11.4% during the forecast period from 2026-2034.
Q2. What is the market size of the Smart Insulin Pens market?
The Smart Insulin Pens market is estimated at USD 0.92 billion in 2025 and is projected to reach USD 2.42 billion by 2034.
Q3. Which region dominates the Smart Insulin Pens market?
North America dominated the Smart Insulin Pens market with a 44% share of global revenue in 2025, supported by high diagnosed diabetes prevalence, favorable reimbursement, deep CGM penetration, and the concentration of leading manufacturers including Medtronic, Eli Lilly, and Abbott. Asia-Pacific is the fastest-growing region over the forecast period.
Q4. What are the key drivers of the Smart Insulin Pens market?
The principal drivers are the rising global burden of diabetes, with the International Diabetes Federation estimating 589 million adults living with diabetes in 2024 and projecting 853 million by 2050; growing demand for personalized, data-driven diabetes management; expanding integration between smart pens and continuous glucose monitoring systems; strategic investment by major insulin manufacturers; rising smartphone and digital health app penetration; and accelerating consolidation and M&A activity.
Q5. Who are the major players in the Smart Insulin Pens market?
The major players include Emperra GmbH E-Health Technologies, Jiangsu Delfu Medical Device Co., Ltd., Medtronic, Novo Nordisk A/S, Pendiq, Sanofi, Berlin-Chemie, Bigfoot Biomedical, Digital Medics Pty Ltd., and Eli Lilly and Company, among other active providers profiled in the Competitive Landscape section. Medtronic, Novo Nordisk A/S, Sanofi, and Eli Lilly and Company lead through branded insulin ecosystem integration and global distribution reach.
Table of Contents
1. Smart Insulin Pens Market Report Introduction
- 1.1 Scope of the Study
- 1.2 Market Segmentation
- 1.3 Market Assumptions
2. Smart Insulin Pens Market Executive Summary
- 2.1 Market at a Glance
3. Smart Insulin Pens Market Key Factors Analysis
- 3.1 Smart Insulin Pens Market Drivers
- 3.1.1 Rising Global Diabetes Burden
- 3.1.2 Demand for Personalized, Data-Driven Diabetes Management
- 3.1.3 Integration with Continuous Glucose Monitoring Systems
- 3.1.4 Strategic Investment by Insulin Manufacturers
- 3.2 Smart Insulin Pens Market Restraints and Challenges
- 3.2.1 Device Cost and Reimbursement Inconsistency
- 3.2.2 Data Privacy and Interoperability Concerns
- 3.2.3 Awareness Gaps in Emerging Markets
- 3.3 Smart Insulin Pens Market Opportunities
- 3.3.1 CGM and Closed-Loop Decision Support Expansion
- 3.3.2 Emerging-Market and Smart-Cap Retrofit Growth
4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
5. Regulatory Analysis
- 5.1 United States
- 5.2 Europe
- 5.3 Japan
- 5.4 China
6. Smart Insulin Pens Market Porter's Five Forces Analysis
- 6.1 Bargaining Power of Suppliers
- 6.2 Bargaining Power of Buyers
- 6.3 Threat of New Entrants
- 6.4 Threat of Substitutes
- 6.5 Competitive Rivalry
7. Smart Insulin Pens Market Assessment
- 7.1 By Connectivity Type
- 7.1.1 Bluetooth-Enabled
- 7.1.2 NFC-Enabled
- 7.1.3 USB-Connected
- 7.1.4 Wireless/Cloud-Connected
- 7.2 By End-Users
- 7.2.1 Hospitals & Clinics
- 7.2.2 Homecare Settings
- 7.2.3 Diabetes Specialty Centers
- 7.2.4 Ambulatory Care Centers
- 7.2.5 Others
- 7.3 By Distribution Channels
- 7.3.1 Hospital & Retail Pharmacy
- 7.3.2 Diabetic Clinics & Centers
- 7.3.3 E-commerce
- 7.3.4 Others
- 7.4 By Geography
- 7.4.1 North America
- 7.4.1.1 United States Smart Insulin Pens Market Size in USD million (2023-2034)
- 7.4.1.2 Canada Smart Insulin Pens Market Size in USD million (2023-2034)
- 7.4.1.3 Mexico Smart Insulin Pens Market Size in USD million (2023-2034)
- 7.4.2 Europe
- 7.4.2.1 Germany Smart Insulin Pens Market Size in USD million (2023-2034)
- 7.4.2.2 United Kingdom Smart Insulin Pens Market Size in USD million (2023-2034)
- 7.4.2.3 France Smart Insulin Pens Market Size in USD million (2023-2034)
- 7.4.2.4 Italy Smart Insulin Pens Market Size in USD million (2023-2034)
- 7.4.2.5 Spain Smart Insulin Pens Market Size in USD million (2023-2034)
- 7.4.2.6 Rest of Europe Smart Insulin Pens Market Size in USD million (2023-2034)
- 7.4.3 Asia-Pacific
- 7.4.3.1 China Smart Insulin Pens Market Size in USD million (2023-2034)
- 7.4.3.2 Japan Smart Insulin Pens Market Size in USD million (2023-2034)
- 7.4.3.3 India Smart Insulin Pens Market Size in USD million (2023-2034)
- 7.4.3.4 Australia Smart Insulin Pens Market Size in USD million (2023-2034)
- 7.4.3.5 South Korea Smart Insulin Pens Market Size in USD million (2023-2034)
- 7.4.3.6 Rest of Asia-Pacific Smart Insulin Pens Market Size in USD million (2023-2034)
- 7.4.4 Rest of World
- 7.4.4.1 Middle East Smart Insulin Pens Market Size in USD million (2023-2034)
- 7.4.4.2 Africa Smart Insulin Pens Market Size in USD million (2023-2034)
- 7.4.4.3 South America Smart Insulin Pens Market Size in USD million (2023-2034)
- 7.4.1 North America
8. Smart Insulin Pens Market Competitive Landscape
- 8.1 Market Concentration and Structure
- 8.2 Competitive Positioning and Market Share Analysis (Premium Offering)
9. Smart Insulin Pens Market Startup Funding and Investment Trends
10. Smart Insulin Pens Market Company and Product Profiles
- 10.1 Emperra GmbH E-Health Technologies
- 10.1.1 Company Overview
- 10.1.2 Company Snapshot
- 10.1.3 Financial Overview
- 10.1.4 Service Portfolio
- 10.1.5 Strategic Initiatives / Entropy
- 10.2 Jiangsu Delfu Medical Device Co., Ltd.
- 10.2.1 Company Overview
- 10.2.2 Company Snapshot
- 10.2.3 Financial Overview
- 10.2.4 Product Portfolio
- 10.2.5 Strategic Initiatives / Entropy
- 10.3 Medtronic
- 10.3.1 Company Overview
- 10.3.2 Company Snapshot
- 10.3.3 Financial Overview
- 10.3.4 Product Portfolio
- 10.3.5 Strategic Initiatives / Entropy
- 10.4 Novo Nordisk A/S
- 10.4.1 Company Overview
- 10.4.2 Company Snapshot
- 10.4.3 Financial Overview
- 10.4.4 Product Portfolio
- 10.4.5 Strategic Initiatives / Entropy
- 10.5 Pendiq
- 10.5.1 Company Overview
- 10.5.2 Company Snapshot
- 10.5.3 Financial Overview
- 10.5.4 Product Portfolio
- 10.5.5 Strategic Initiatives / Entropy
- 10.6 Sanofi
- 10.6.1 Company Overview
- 10.6.2 Company Snapshot
- 10.6.3 Financial Overview
- 10.6.4 Product Portfolio
- 10.6.5 Strategic Initiatives / Entropy
- 10.7 Berlin-Chemie
- 10.7.1 Company Overview
- 10.7.2 Company Snapshot
- 10.7.3 Financial Overview
- 10.7.4 Product Portfolio
- 10.7.5 Strategic Initiatives / Entropy
- 10.8 Bigfoot Biomedical
- 10.8.1 Company Overview
- 10.8.2 Company Snapshot
- 10.8.3 Financial Overview
- 10.8.4 Product Portfolio
- 10.8.5 Strategic Initiatives / Entropy
- 10.9 Digital Medics Pty Ltd.
- 10.9.1 Company Overview
- 10.9.2 Company Snapshot
- 10.9.3 Financial Overview
- 10.9.4 Product Portfolio
- 10.9.5 Strategic Initiatives / Entropy
10. Eli Lilly and Company
- 10.10.1 Company Overview
- 10.10.2 Company Snapshot
- 10.10.3 Financial Overview
- 10.10.4 Product Portfolio
- 10.10.5 Strategic Initiatives / Entropy
For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.
